Current Research Studies

Cancer – PLAT-07: A Phase 1/2 Study of CD22-Specific Car T Cells for CD22+ Leukemia or Lymphoma

What is the goal of this study?

PLAT-07 is a phase 1/2 clinical trial. The study is currently in Phase 1. Phase 1 trials focus on finding out how much of a therapy to give, how to give it, how often to give it and when side effects occur. 

Through the PLAT studies, researchers are working to answer these questions:

  1. How safe are the CAR T cells?
  2. What are the side effects of the CAR T cells?
  3. How well does this CAR T cell treatment fight cancer in patients who have not have not had CAR T cell therapy before and patients who have had CAR T cell therapy before?
  4. How long do the CAR T cells stay in your body?
  5. How do CAR T cells act inside your body?

Phase 2 studies test treatments to find out how well they work and to get more safety information.

Who can join the study?

The PLAT-07 study is for children and young adults who:

  • Have relapsed or refractory leukemia or lymphoma
  • Are ages 0 to 30 years old

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

Patients who have CD22-positive (CD22+) leukemia or CD22+ lymphoma that does not go away with treatment (is refractory) or comes back after treatment (is recurrent) often stay sick. Giving more chemotherapy does not usually help them get better.

This study is testing a treatment that works differently from chemotherapy. It uses the body’s own immune system to kill the cancer cells. White blood cells normally fight infections in your body. If white blood cells become cancerous, the cancer is called leukemia or lymphoma. CD22 is a protein that is normally found on the surface of white blood cells. When white blood cells become cancerous, they still have CD22 protein on them. T cells are normal cells in the body that fight disease when we are sick. Our bodies teach our T cells not to attack our own cells. Since cancer cells come from our own body, it is hard for T cells to recognize and kill cancer cells. Researchers can change T cells so the T cells have a chimeric antigen receptor (CAR) that can recognize CD22 protein. Once the T cells are programmed to recognize the CD22 protein on the tumor cells they can target those cells to kill them.

In this study, researchers will take some of your blood and remove the T cells. Then the T cells are taken to a lab and changed to recognize CD22. Once researchers believe there are enough CAR T cells to fight your cancer, they will put the CAR T cells back in your body. 

Who can I contact for more information?

For more information, call 206-987-2106 or send us an email.

Learn about other PLAT studies at Seattle Children's:

  • PLAT-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T-Cell Immunotherapy for CD19+ Leukemia
  • PLAT-03: A Pilot Feasibility and Safety Study of CD19t T-APC Vaccination Following CAR T-Cell Immunotherapy for CD19+ Leukemia
  • PLAT-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T-Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
  • PLAT-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Corinne Summers
Research Center: Center for Clinical and Translational Research